Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.68 USD | -0.97% | -14.37% | -43.11% |
May. 23 | Transcript : Scholar Rock Holding Corporation Presents at UBS Obesity Therapeutics Day, May-23-2024 09:00 AM | |
May. 22 | Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 28.82M | Capitalization | 861M |
---|---|---|---|---|---|
Net income 2024 * | -235M | Net income 2025 * | -229M | EV / Sales 2024 * | - |
Net cash position 2024 * | 256M | Net cash position 2025 * | 365M | EV / Sales 2025 * | 17.2 x |
P/E ratio 2024 * |
-4.5
x | P/E ratio 2025 * |
-5.16
x | Employees | 150 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.69% |
Latest transcript on Scholar Rock Holding Corporation
1 day | -7.86% | ||
1 week | -24.65% | ||
Current month | -26.45% | ||
1 month | -27.05% | ||
3 months | -30.83% | ||
6 months | -4.77% | ||
Current year | -42.61% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Backstrom
CEO | Chief Executive Officer | 69 | 22-09-19 |
Edward Myles
DFI | Director of Finance/CFO | 52 | 18-11-18 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 22-07-25 | |
Michael Gilman
BRD | Director/Board Member | 69 | 13-10-31 |
Edward Myles
DFI | Director of Finance/CFO | 52 | 18-11-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.00% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 10.7 | -0.88% | 337 533 |
24-05-23 | 10.79 | -7.86% | 1,142,332 |
24-05-22 | 11.71 | -4.56% | 974,114 |
24-05-21 | 12.27 | -2.00% | 888,302 |
24-05-20 | 12.52 | +0.24% | 728,352 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.61% | 861M | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.52% | 21.58B | |
-11.32% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- SRRK Stock